Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis (Q38695705)

5 September 2017

title

Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis (English)

1 reference

5 September 2017

0 references

1

Charles A Dinarello

1 reference

5 September 2017

2

Leo A B Joosten

1 reference

5 September 2017

language of work or name

English

0 references

publication date

14 January 2016

1 reference

Nature Reviews Rheumatology

5 September 2017

published in

1 reference

5 September 2017

volume

12

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

78-80

1 reference

Acute-phase protein α1-antitrypsin--a novel regulator of angiopoietin-like protein 4 transcription and secretion.

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Secukinumab failure in Crohn's disease: the yeast connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.180

31 March 2020

Identifiers

DOI

10.1038/NRRHEUM.2015.180

1 reference

Dimensions Publication ID

5 September 2017

1049993737

0 references

1 reference